Clinically, although analysis of public SCLC cohorts revealed a trend toward poorer survival in patients with higher KDM6B expression, this did not reach statistical significance, likely due to the limited sample sizes, incomplete treatment annotation, and the rapid clinical course of SCLC.
← all excerpts
KDM6B inhibition enhances chemotherapeutic response in small cell lung cancer via epigenetic regulation of apoptosis and ferroptosis.
1
—
—